








Identification and functional analyses of CBS alleles in 
Spanish and Argentinian homocystinuric patients 
 
 
Journal: Human Mutation 
Manuscript ID: humu-2010-0637.R1 
Wiley - Manuscript type: Research Article 
Date Submitted by the 
Author: 
31-Mar-2011 
Complete List of Authors: Cozar, Monica; Universitat de Barcelona, Departament de Genetica; 
CIBERER; IBUB 
Urreizti, Roser; Universitat de Barcelona, Departament de Genetica; 
CIBERER; IBUB 
VILARINHO, Laura; Medical Genetics Institute, Clinical Biology 
Grosso, Carola; Universidad Nacional de Córdoba Hospital de Niños, 
Centro de Estudio de las Metabolopatías Congénitas, CEMECO, 
Facultad de Ciencias Médicas 
Dodelson de Kremer, Raquel; Universidad Nacional de Córdoba 
Hospital de Niños, Centro de Estudio de las Metabolopatías 
Congénitas, CEMECO, Facultad de Ciencias Médicas 
Asteggiano, Carla; Children's Hospital of Santisima Trinidad, 
CEMECO 
Dalmau, Jaime; Hospital Infantil La Fe, Division of Metabolism, 
Garcia, Ana; Hospital Infantil La Fe, Division of Metabolism, 
Vilaseca, María; Hospital Sant Joan de Déu, Bioquímica 
Grinberg, Daniel; Universitat de Barcelona, Departament de 
Genetica; CIBERER; IBUB 
Balcells, Susana; Universitat de Barcelona, Departament de 
Genetica; CIBERER; IBUB 
Key Words: 
CBS mutations, homocystinuria, Southern blot, mini-gene, 










Identification And Functional Analyses of CBS Alleles In Spanish And 
Argentinian Homocystinuric Patients  
Mónica Cozar,1* Roser Urreizti,1* Laura Vilarinho,2 Carola Grosso,3 Raquel Dodelson 
de Kremer,3 Carla G. Asteggiano,3 Jaime Dalmau,4 Ana María García,4 María Antonia 
Vilaseca,5 Daniel Grinberg,1* and Susana Balcells1*#  
 
1 Departament de Genètica, Universitat de Barcelona, IBUB, Centro de Investigación 
Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Barcelona, Spain 
2 Instituto de Genética Médica Jacinto Magalhaes, Porto, Portugal 
3 Centro de Estudio de las Metabolopatías Congénitas (CEMECO), Facultad de 
Ciencias Médicas, Universidad Nacional de Córdoba, Hospital de Niños de la 
Santísima Trinidad, Córdoba,  Argentina. 
4 Unidad de Nutrición y Metabolopatías. Hospital Infantil La Fe, Valencia, Spain. 
5 Servei de Bioquímica. Hospital Sant Joan de Déu, Barcelona, Spain. 
 
* Equal contributors. 
#  Correspondence to: Dr. Susana Balcells, Departament de Genètica, Facultat de 
Biologia, Universitat de Barcelona, Av. Diagonal 645, E-08028, Barcelona, Spain.   
Email: sbalcells@ub.edu 
Tel.: +34 93 403 5418 
Fax: +34 93 403 4420 
Page 1 of 27

































































ABSTRACT: Homocystinuria due to CBS deficiency (MIM#236200) is a rare 
autosomal recessive disorder characterized by elevated plasma levels of 
homocysteine (Hcy) and methionine (Met). Here we present the analysis of 22 
unrelated patients of different geographical origins, mainly Spanish and Argentinian. 
Twenty-two different mutations were found, ten of which were novel. Five new 
mutations were missense and five were deletions of different sizes, including a 794-
bp deletion (c.532-37_736+438del794) detected by Southern blot analysis. To assess 
the pathogenicity of these mutations, seven were expressed heterologously in E. coli 
and their enzyme activities were assayed in vitro, in the absence and presence of the 
CBS activators PLP and SAM. The presence of the mutant proteins was confirmed by 
Western-blotting. Mutations p.M173del, p.I278S, p.D281N and p.D321V showed null 
activity in all conditions tested, while mutations p.49L, p.P200L and p.A446S retained 
different degrees of activity and response to stimulation. Finally, a minigene strategy 
allowed us to demonstrate the pathogenicity of an 8-bp intronic deletion, which led 
to the skipping of exon 6. In general, frameshifting deletions correlated with a more 
severe phenotype, consistent with the concept that missense mutations may recover 
enzymatic activity under certain conditions.  
 
KEY WORDS: CBS mutations; homocystinuria; Southern blot; mini-gene; 
heterologous expression; enzyme activity 
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Homocysteine (Hcy) is a sulfur-containing amino acid that occupies a major 
regulatory branch point in methionine metabolism. Homocysteine may be either 
remethylated to methionine or catabolized to form cysteine through the 
transsulfuration pathway. The first step of transsulfuration involves the 
condensation of homocysteine with serine to form cystathionine, a reaction catalyzed 
by the enzyme cystathionine β-synthase (CBS; EC 4.2.1.22).  
Mutations in the CBS gene (MIM# 613381) cause classical homocystinuria (Hcu, 
MIM# 236200), an autosomal recessive disease characterized by severe 
hyperhomocysteinemia and homocystinuria, decreased plasma levels of cysteine 
and, often, hypermethioninemia. At the clinical level, classical homocystinuria 
mainly affects the eye, the skeleton, the vascular system and the central nervous 
system (CNS). Symptoms usually include ectopia lentis, osteoporosis, scoliosis, 
Marfanoid features, premature arteriosclerosis, thromboembolism and mental 
retardation (Mudd, et al., 1985). Age of onset and disease severity are highly variable, 
ranging from dramatically affected children to asymptomatic adults (Magner, et al., 
2011; Skovby, et al., 2010; Walter, et al., 1998; Yap and Naughten, 1998). Treatments 
that lower tHcy, such as B-vitamins, dietary methionine restriction, and betaine 
supplementation, can significantly reduce the incidence of vascular events (the main 
cause of death in these patients) and improve the neurological problems (Wilcken 
and Wilcken, 1997; Yap, et al., 2001; Yap and Naughten, 1998).  
Homocystinuria is a rare disease with variable incidence. While the worldwide 
incidence is estimated as 1/344000 born alive (Mudd, et al., 1995), in Qatar it is 
1/3124 (El-Said, et al., 2006) and in Japan 1/800 000 (Mudd, et al., 1995). In Northern 
Europe the incidence may be of 1/20500 to 1/6400, as estimated from the high 
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number of p.I278T mutation carriers found in some populations (Gaustadnes, et al., 
1999; Refsum, et al., 2004). 
To date, more than 150 different CBS mutations have been found worldwide, 
some of them common. Mutation p.I278T is considered panethnic and is particularly 
frequent in Northern Europe (Janosik, et al., 2001b; Kraus, et al., 1999; Moat, et al., 
2004). In Ireland, the p.G307S mutation accounts for 71% of the mutant alleles 
(Gallagher, et al., 1995), and in the Iberian Peninsula and Colombia, mutation 
p.T191M represents between 40% and 75% (Urreizti, et al., 2006a) of the mutant 
alleles. 
A truncated form of the human CBS enzyme lacking the C-terminal regulatory 
domain has been crystallized (Janosik, et al., 2001a; Meier, et al., 2001) and 
structurally characterized (Banerjee and Zou, 2005; Kabil, et al., 2001; Kery, et al., 
1999; Meier, et al., 2001; Taoka, et al., 2002). The active form of this cytoplasmic 
enzyme is a homotetramer of four 63-KDa subunits. Each subunit combines one 
heme group and one pyridoxal phosphate (PLP), the latter acting as a cofactor in the 
reaction. In addition, each subunit binds the allosteric activator S-Adenosil-
Methionine (S-AdoMet or SAM), an intermediate in the methionine cycle. 
Heterologous expression in E. coli has been widely used to test the functionality of 
the CBS mutant alleles independently from the patient’s genetic background (de 
Franchis, et al., 1994; Katsushima, et al., 2006; Maclean, et al., 2002). It has been 
proven to be a useful tool since the E. coli-expressed human CBS is indistinguishable 
from that obtained from cultured fibroblasts (Bukovska, et al., 1994; Kozich and 
Kraus, 1992). In addition, in vitro, its relative activity in response to PLP and SAM is 
comparable to that of the enzyme obtained from human tissues (Bukovska, et al., 
1994; Kozich and Kraus, 1992). 
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This study updates the CBS mutation spectrum of the homocystinuric patients 
from the Iberian Peninsula by presenting the analysis of 16 new cases. It also includes 
one Norwegian, one Indian and four Argentinian patients. In this cohort of 22 cases, 
22 mutations were found, ten of which were novel. The new mutations include a 
deletion of 794 bp (c.532-37_736+438del794) detected by Southern blot analysis and 
an intronic deletion that leads to the skipping of exon 6, which was characterized 
using a minigene strategy. The pathogenic role of seven of the changes was assessed 




Materials And Methods 
Patients 
Twenty-six patients with classical homocystinuria from 22 unrelated pedigrees 
were involved in this study. Patients were initially diagnosed by their physicians on 
the basis of clinical manifestations suggestive of homozygous CBS deficiency. 
Biochemically, these patients presented with a combination of severe 
hyperhomocysteinemia (typically above 150 µmol/l), and hypermethioninemia 
(typically above 40 µmol/l). Thirteen Spanish, three Portuguese, one Norwegian, one 
Indian and four Argentinian patients were included in the study. Our research was 
conducted in accordance with the tenets of the Declaration of Helsinki. The nature 
and possible consequences of the study were first explained to all patients and/or 
their parents, before their informed consent for inclusion in the research project was 
obtained. 
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PCR amplification and DNA sequencing 
Genomic DNA was prepared from peripheral blood leukocytes, using a Wizard 
Genomic DNA Purification Kit (Promega, Madison, WI, USA). 
All 16 CBS coding exons (including exon 15) and their intronic flanking regions, 
were amplified by PCR and sequenced as described previously (Urreizti, et al., 
2006a) with some modifications. Briefly, PCR reactions were performed on a final 
volume of 50 µl with 50 ng gDNA, 0.2 mM of each dNTP, 0.4 mM of each primer, 
1.5–2.5 mM MgCl2 and 1.25 U of GoTaq
®
 Flexi DNA Polymerase (Promega, Madison, 
WI, USA). All mutations detected were confirmed by restriction analysis of the PCR 
products with the appropriate restriction enzyme, and the presence of all new 
mutations was assessed in 100 control chromosomes from Spanish anonymous 
donors. Primer sequences and PCR conditions have been described previously 
(Urreizti, et al., 2006a). MTHFR c.677C>T (rs1801133) was analyzed in all patients as 
described in Frosst et al. (Frosst, et al., 1995).  
To characterize the deletion found in patient 87, genomic DNAs of the patient 
and her parents were PCR-amplified using primers 4F and 7R as described above 
with the addition of a final concentration of 5% DMSO. The PCR fragments were 
purified and sequenced. 
For naming the mutations the following reference sequences were used: 
Genomic, GenBank NG_008938.1; cDNA, ENST00000352178. Nucleotide numbering 
reflects cDNA numbering with +1 corresponding to the A of the ATG translation 
initiation codon in the reference sequence, according to journal guidelines 
(www.hgvs.org/mutnomen). The initiation codon is codon 1. 
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A Southern blot to analyze a 36-kb fragment of the CBS genomic region (Fig. 1), 
between two DrdI sites, encompassing all 23 exons, plus 6 kb of the 5’ flanking region 
and 11.5 kb of the 3’ region, was performed as follows: 10 µg of patient and control 
gDNA were double digested by DrdI and AflII (NEBiolabs, Ipswich, MA, USA), 
electrophoresed on a 0.9% agarose gel, blotted onto Amersham HybondTM-N+ (GE 
Healthcare, Waukesha, WI, USA) membrane using standard protocols, and fixed by 
UV crosslinking. The DrdI/AflII double digestion of the 36 kb yields, in a wild-type 
setting, four fragments of around 15 kb, 10 kb, 8 kb and 3 kb, respectively (Fig. 1A). 
 
Probe design, preparation and hybridization  
Four probes were designed by selecting one unique sequence of approximately 
600 bp within each restriction fragment. The sequences were aligned to the whole 
genome by BLAST, to confirm their specificity. These four sequences were PCR-
amplified from total genomic DNA (as described above), cloned into pUC19 vector 
(Fermentas, Burlington, ON, Canada) and sequenced. Probes were obtained from the 
clones by using digoxigenin-dUTP and the “PCR DIG Probe Synthesis Kit” (Roche, 
Mannheim, Germany), according to the manufacturer’s instructions. Primer 
sequences for the probes are available on request. Labelled probes were subsequently 
purified using IllustraTM GFXTM PCR DNA and a Gel Band Purification Kit (GE 
Healthcare, Waukesha, WI, USA).  
All subsequent steps of the Southern protocol (prehybridization, hybridization 
and developing of the filters) were performed using reagents (Dig Easy Hyb) and 
protocols (Dig Application Manual) from Roche (Mannheim, Germany).  
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Site-directed mutagenesis, heterologous expression and in vitro enzyme activity 
assays of the CBS mutations 
All CBS mutant constructs were derived from the wild-type CBS expression 
plasmid pHCS3 (Kozich and Kraus, 1992), a gift from the authors of that study. Each 
mutation was introduced into the wild-type expression plasmid using a Quik 
Change II XL TM Site-Directed Mutagenesis Kit (Stratagene Cloning Systems, La Jolla, 
CA, USA) and expressed in XL-Gold E. coli cells as described in Urreizti et al. 
(Urreizti, et al., 2006b). Expression of pHCS3 was used as a positive control, and that 
of the empty vector pKK388.1 was included as a negative control. Protein extracts 
were obtained and CBS activity was measured as described in Kraus (Kraus, 1987) 
with some modifications (Urreizti, et al., 2006b). 
 
CBS protein analysis 
To assess the presence and relative amount of wild-type and mutant CBS 
proteins, Western blot analysis of the soluble fraction of the crude cell lysates was 
performed under denaturing conditions as described in Janosik et al. (Janosik, et al., 
2001b), with some modifications (Urreizti, et al., 2006b). 
 
Minigene construction and splicing assay 
Genomic DNA from patient 68a (heterozygote for mutation c.667-14_-7del8) 
was amplified using CBS primers 4F and 6R to obtain a fragment of 626 or 618 bp 
(from the last 29 bp of intron 3 to the first 103 bp of intron 6). This PCR product, 
containing both wild-type and mutant alleles, was purified using IllustraTM GFXTM 
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PCR DNA and a Gel Band Purification Kit (GE Healthcare, Waukesha, WI, USA) and 
cloned into the pGLB1 vector (Diaz-Font, et al., 2005). Plasmid pGLB1 is based on a 
pcDNA3.1 vector and contains exons 7, 8, and 9 and introns 7 and 8 of the GLB1 
gene, where intron 7 contains a PmeI restriction site, which was used to clone the CBS 
fragment. The resulting plasmids, named pGLB1-CBS_wt and pGLB1-CBS_mut, 
were confirmed by sequencing. 
The splicing assay was performed by transfecting 1 µg of each minigene 
plasmid with 5 µl of Lipofectamine 2000 Reagent (Life Technologies, Basel, 
Switzerland) into 90% confluent HeLa cells. Total RNAs were isolated 24 h after 
transfection using the QIAshredder and the RNeasy Mini Kit (QIAGEN, Hilden, 
Germany). RNA concentration was determined spectrophotometrically, integrity was 
verified by gel electrophoresis and RNA quality was assessed by OD 260/230 and 
260/280 ratios. 
Two µg of each RNA was reverse-transcribed in a final volume of 20 µl using a 
High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Applied 
Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. 
PCR amplification of each cDNA product was performed using primers T7 and 
SP6 as previously described (Diaz-Font, et al., 2005; Santamaria, et al., 2008). The PCR 
products were electrophoresed and each band of interest was purified and analyzed 
by sequencing.  
 
Results  
Screening for CBS mutations  
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Twenty-two different mutations (Table 1), ten of them novel, were found in 22 
unrelated patients of different geographical origin (Table 2). Forty-two mutant alleles 
were identified through sequencing of coding exons and flanking intronic regions, 
while an additional mutant allele was discovered by Southern blot analysis (see 
below). Only one allele remained unidentified. Five of the new mutations were 
missense while five were deletions. 
After sequencing the complete CBS coding sequence, only mutation c.1566delG 
was found in heterozygosis in patient 87, which she inherited from her father. A 
Southern blot analysis f this patient and her mother, hybridized with a set of four 
probes covering the entire CBS genomic region (Fig. 1A), revealed the same pattern 
of bands observed in control samples but the relative intensities of fragments 2, 3 and 
4 were altered (Fig. 1B). Hybridization of the same membrane separately with each 
individual probe revealed an additional band of nearly 10 kb detected by probes B 
and C (Fig. 1C). This result was consistent with a deletion removing the DrdI site 
present in intron 5. To test this hypothesis, a PCR amplification from intron 3 to 
intron 7 was performed. As shown in Fig. 1D, a new band of 1176 bp was observed in 
the samples of the patient and her mother. Sequencing revealed a 796-bp deletion 
(c.532-37_736+438del794), which spans from the last 37 bp of intron 4 to the first 438 
bp of intron 6 (Fig. 1E). This deletion causes a frameshift starting from a valine to 
glycine substitution at position 178 and leading to a stop codon at residue 201 
(p.V178GfsX23).  
 
Analyses of pathogenicity of mutant CBS enzymes 
None of the new mutations found was present in 100 control chromosomes, 
ruling out the possibility of common polymorphisms. 
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We assessed the pathogenicity of all five new missense mutations and of the 
novel in-frame deletion p.M173del using an E. coli heterologous expression system 
followed by Western blot and in vitro enzyme activity analysis (Fig. 2). Mutation 
p.P49L, previously described by de Franchis et al. (de Franchis, et al., 1998) was also 
analyzed.  
All the proteins from the mutant alleles were found in amounts similar to those 
of the wild type (Fig. 2, upper panel). The activity of these mutant enzymes was 
assayed in vitro, either in the presence or absence of the cofactor PLP, or in the joint 
presence of PLP and SAM (Fig. 2, lower panel). As previously described (Kluijtmans, 
et al., 1996; Maclean, et al., 2002), we found that the wild-type CBS activity was 
strongly stimulated by both PLP and the combination of PLP and SAM. Mutations 
p.M173del, p.I278S, p.D281N and p.D321V showed null activity, either in the absence 
or presence of the activators. In contrast, mutations p.49L, p.P200L and p.A446S 
retained different amounts of activity and also the ability to be stimulated.  
In particular, mutation p.P49L displayed null activity in the absence of any of 
the activators, retained 71% of the wild-type activity in the presence of PLP and 
showed reduced activation by SAM. In contrast, in the absence of any of the 
activators, mutation p.P200L displayed around a third of the activity of the wild type 
(15% versus 43%) and retained the ability to be induced by PLP and SAM. SAM 
stimulation was 2-fold, comparable to that of the wild type. Finally, p.A446S 
displayed highly variable levels of activity in different tests, in the absence or 
presence of activators, but in general the values where in the range of the wild type 
or higher.  
 
Effect of a small intronic deletion on RNA splicing 
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The small deletion c.667-14_-7del8 involved intron 5 sequences within the 
acceptor site, without affecting the conserved AG dinucleotide. Since no RNA was 
available from patients with this mutation (68a and 68b), a minigene assay was 
performed to test the effect of this mutation on RNA splicing (Fig. 3A). The genomic 
region spanning from the 3’ part of intron 3 to the 5’ part of intron 6 of the CBS gene 
of the mutant and wild-type alleles was PCR-amplified and cloned within intron 7 of 
a construct containing several GLB1 exons (see Material and Methods for details). 
Wild-type and mutant constructs were transfected into HeLa cells and splicing was 
assayed by RT-PCR using the T7 and SP6 primers (Fig. 3B). The major band observed 
in the wild-type sample corresponds to the inclusion of all three CBS exons, whereas 
in the mutant, exon 6 was skipped, as assessed by sequencing of all the bands. 
 
Discussion 
Mutation p.T191M was identified in 21.8% of the alleles of the Spanish and 
Portuguese patients included in this study (Table 2). Taking into consideration all 50 
homocystinuric patients from the Iberian Peninsula included in this and in our 
previous studies (Urreizti, et al., 2003; 2006a), mutation p.T191M accounts for 44% of 
the mutant chromosomes. Mutation c.1566delG is the second most prevalent change 
(7% overall), and is particularly common in Portugal (21%). In the present study, we 
found the panethnic mutation p.I278T for the first time in two unrelated Spanish 
patients, both in the heterozygote state, and in a Norwegian patient, in homozygosis 
(Table 2). Missense mutations are the most common alterations in the CBS gene in 
the patients of the present study (73%). We also found six deletions of different sizes 
(1 bp to 794 bp), five of them novel.  
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Southern blot analysis allowed us to identify a large deletion of nearly 800 bp in 
the heterozygous state (c.532-37_736+438del794, p.V178GfsX23) in patient 87 and in 
her mother. Additionally, a qmfPCR assay was performed on the patient’s sample 
yielding a consistent result (C. Ged, personal communication). This patient, 
diagnosed through neonatal screening, presented with dramatically increased 
plasma methionine (700 µM) and total homocysteine (145 µM). She has been on a 
normal diet and treated with pyridoxal, folate and betaine since her birth. Currently 
aged 4 years, her plasma homocysteine and methionine levels are 76 µM and 302 µM, 
respectively, and she is clinically asymptomatic, highlighting the importance of an 
early diagnosis.  
An intronic 8-bp deletion (c.667-14_-7del8) was found in two siblings (#68a-
#68b, Table 2). Prediction algorithms indicated a subtle reduction in the score of the 
splicing acceptor site of intron 5. However, a mini-gene analysis clearly showed that 
it led to the skipping of exon 6, and produced a frameshift. This is consistent with the 
severity of the patients’ phenotypes. We also found a 5 bp deletion in exon 8 in 
patient #109, and a 1 bp deletion in exon 6 in patient #89, both in homozygosis (Table 
2). The severity of these genotypes is in accordance with the severe clinical 
presentation of both patients. In general, frameshift-generating deletions correlate 
with a more consistently severe phenotype, as expected.  
Seven mutations (six missense and a 3-bp deletion) were expressed in E. coli 
and analyzed by Western blot under denaturing conditions (Fig. 2, upper panel). 
Their presence in amounts similar to those of the wild-type CBS suggests that the 
mutations do not affect protein integrity. Alternatively, they may affect the catalytic 
core, proper protein folding or the ability to form tetramers. In this regard, several 
authors have studied the involvement of certain chaperones in the rescue of missense 
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CBS mutants, and demonstrated that the regulation of these chaperones could lead to 
almost complete recovery of the mutant protein activity (Kopecka, et al., 2010; 
Majtan, et al., 2010; Singh, et al., 2007; Singh, et al., 2010).  
Four mutations showed null activity, which supports their pathogenic 
character. These mutations, p.D281N, p.I278S, p.D321V and p.M173del, were found 
in four unrelated patients, #82a (and his siblings), #94, #90, and #55, respectively. No 
correlation between their null activity and the phenotypes of the patients could be 
established since all but patient #94 presented with mild disease. 
The other three mutations, displaying different degrees of enzyme activity, 
were p.P49L, p.P200L and p.A446S, present in patients #80, #79 and #90, 
respectively, all in the heterozygous state. In these cases, a correlation between their 
residual activity and the mild phenotype of the patients was observed. 
We found the activity of p.P49L to be 75% of that in the wild type. While our 
work was ongoing, Kozich et al. (Kozich, et al., 2010) published an analysis of 
mutation p.P49L expressed in E. coli. They found it to be an active enzyme, 
indistinguishable from the wild type. Mutation p.P49L was found in two siblings, 
one with adult onset and the other asymptomatic. Genetic analysis of the proband 
(#80a in Table 2 and subject II.1 in Fig. 4), showed compound heterozygosity for 
p.P49L and p.R125Q (Table 2). Genotyping of his siblings revealed an asymptomatic 
sister also carrying both mutations (#80b; II.3 in Fig. 4). The proband had suffered a 
myocardial infarction at age 53. Blood testing revealed moderate 
hyperhomocysteinemia and hypermethioninemia (58 and 655 µM, respectively) and 
he responded well to PLP (tHcy: 28 µM after treatment). On the other hand, his 
asymptomatic sister, aged 54, presented with severe hyperhomocysteinemia (543 
µM) and hypermethioninemia (1723 µM) but had no clinical sign of classical 
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homocystinuria and had given birth to three healthy offspring without 
complications. As the two CBS mutations were inherited separately by the offspring, 
we know that they were not in cis in the mother or in his affected brother. Mutation 
p.R125Q, the other mutation in family #80, was originally described as a null activity 
mutation (Sebastio, et al., 1995). In their recent publications, Kozich et al. (Kozich, et 
al., 2010) and Majtan et al. (Majtan, et al., 2010) expressed it in E. coli. In both studies 
the reduced activity was improved under permissive conditions or in the presence of 
chaperones. Taken together, these new results on p.P49L and p.R125Q help explain 
the mild or null affectation of patients #80a and #80b. In addition, the MTHFR 
677C>T polymorphism may act as a phenotype modifier in this family. However, the 
discrepancy between the blood markers and the phenotype of patient #80b remains 
unexplained. 
Mutation p.P200L was identified as the sole mutation in patient #79. The 
patient’s symptoms are limited to hypertension and severe hyperhomocysteinemia 
(183 µM), which does not respond to vitamin B6 and folate treatment. A second CBS 
mutation may be deep intronic, located in a regulatory region far from the gene, or 
involved in a complex rearrangement not detected by our screening methods. 
Mutation p.A446S was found in a mildly affected patient (#90, Table 2), in compound 
heterozygosis with the null mutation p.D321V (Fig. 2). The activity of p.A446S was 
very similar to that of the wild type and this correlates with the mild phenotype of 
the patient, who only presented with lens dislocation at 45 years, despite a high tHcy 
level (105 µM, which was reduced to 40 µM after two months of treatment with folic 
acid and vitamins B6 and B12).  
The poor genotype–phenotype correlation widely observed by us and others 
among the homocystinuric patients and the demonstration that some patients 
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carrying two CBS mutant alleles are asymptomatic, call for environmental and 
genetic modifiers involved in the pathophysiology of the disease. Some of these 
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Figure 1. Southern Blot analysis of the CBS gene. A: scheme of the human CBS gene. 
The DrdI (D) and AflII (A) restriction sites and the corresponding restriction 
fragments (F1 to F4) are indicated below the scheme. The positions of the probes (A 
to D) are indicated above. B: Southern Blot analysis of patient #87 and her mother 
(#87m) hybridized with the whole set of probes. Two wild-type DNAs were included 
in the analysis. M: Molecular weight marker. C: Southern Blot analysis hybridized 
with probe B. The arrow indicates the new band found in the patient and her mother. 
D: PCR amplification of the fragment from intron 3 to intron 7. An extra band of 
reduced size was found in patient 87 and her mother, corresponding to a 794-bp 
deletion. The asterisk indicates the heteroduplex. E: Chromatogram of patient 87 
showing the deletion boundaries.  
 
Figure 2. Heterologous expression and activity of seven CBS mutations. A: SDS-
PAGE followed by Western blot immunodetection of wild-type and mutant CBS 
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proteins expressed in E. coli XL Gold. Ten µg of total protein extract was loaded in 
each lane. Six replicates were performed for each mutation. pKK: Empty vector used 
as negative control. B: In vitro enzyme activity of wild-type and mutant CBS alleles 
from E. coli XL Gold extracts in the absence of both PLP and SAM (black boxes), in 
the presence of PLP (grey boxes), and in the presence of both PLP and SAM (white 
boxes). Wild-type CBS activity in the presence of PLP was taken as the reference 
value (100%). Activity values greater than 4% are indicated in the figure. Values are 
the means of six replicates. Error bars represent SD.  
 
Figure 3. Splicing analysis of mutation c.667-14_-7del8 included in a minigene 
construction. A: scheme of the minigene: grey boxes represent GLB1 exons and white 
boxes are CBS exons. The thick horizontal line represents the CBS introns and the 
thin line the GLB1 introns. PCMV: CMV promoter; BGHpA: BGH polyadenylation 
site. Wild-type and mutant splicing patterns are indicated above and below the gene 
respectively. The dot indicates the position of the mutation. The wild-type and 
mutant constructs were transiently transfected into HeLa cells. Total RNA was 
extracted 24 h after transfection, reverse-transcribed and PCR-amplified with primers 
T7 and SP6 (indicated by arrows). B: PCR amplification of the wild-type (1) mutant 
(2) and the minigene construct without the CBS exons (3). The asterisk points to a 
minor band lacking exon 4 observed in the wild-type construct. C: Diagrams 
showing the three main PCR products.  
Figure 4. Pedigree of family 80. Patient 80a (II.1), the proband, is marked with an 
arrow. Patient 80b is member II.3. CBS genotypes are indicated below the pedigree 
symbols; the MTHFR c.677C>T genotypes are also included in brackets. Total plasma 
homocysteine levels (µMol/L) are indicated when available. NA: not available. 
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c.146C>T p.P49L Ex 1 1  de Franchis et al., 1998 
c.253G>A p.G85R Ex 2 1  Maclean et al., 2002 
c.361C>T p.R121C Ex 3 1  Katsushima et al., 2006 
c.374G>A p.R125Q Ex 3 1  Marble et al., 1994 
c.518delTGA p.M173del Ex 4 2  This study 
c.532-37_736+438del794 p.V178GfsX23 In 4-In 6 1  This study 
c.572C>T p.T191M Ex 5 7  Urreizti et al., 2003 
c.599C>T p.P200L Ex 5 1 MspI- This study 
c.667-14_667-7del8 p.Y223GfsX23 In 5 1  This study 
c.676G>A p.A226T Ex 6 2  Shan et al., 1998 
c.689delT p.L230RfsX39 Ex 6 1 MspI+ This study 
c.824G>A p.C275Y Ex 7 1  Urreizti et al., 2003 
c.833T>G p.I278S Ex 8 1 TspRi+ This study 
c.833T>C p.I278T Ex 8 4  Kozich et al., 1992 
c.841C>T p.D281N Ex 8 1 BamHI- This study 
c.862_866del5 p.E289GfsX39 Ex 8 2  This study 
c.962A>T p.D321V Ex 9 1 Hpy8I- This study 
c.1085C>T p.T353M Ex 10 2  Dawson et al., 1997 
c.1136G>A p.R379Q Ex 10 1  Urreizti et al., 2003 
c.1330G>A p.D444N Ex 12 4  Kluijtmans et al., 1996 
c.1336G>T p.A446S Ex 12 1 BstNI+ This study 
c.1566delG p.K523SfsX18 Ex 16 5  Castro et al., 1999 
Mutations not previously described are indicated in bold 
1
Novel missense mutations were checked in control chromosomes using the indicated enzyme. +: the 
mutation creates a new site; -: the mutation destroys a site. 
Reference Sequences: Genomic, GenBank NG_008938.1; cDNA, ENST00000352178. Nucleotide 
numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation 
codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The 
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C>T) Severity Country 
74 p.[T353M]+[D444N] TT Severe Spain 
79 p.[P200L]+[?] CT Asymptomatic Spain 
80a p.[R125Q]+[P49L] TT Mild Spain 
80b p.[R125Q]+[P49L] CT Asymptomatic  
82a p.[T191M]+[D281N] CC Mild Spain 
82b p.[T191M]+[D281N] CC Mild  
82c p.[T191M]+[D281N] CC Mild  
83 p.[T353M]+[D444N] TT Mild Spain 
84 p.[I278T]+[R121C] CT Mild Spain 
88 p.[D444N]+[D444N] CT Mild Spain 
92 p.[T191M]+[T191M] CT Mild Spain 
93 p.[T191M]+[T191M] CT Severe  Spain 
94 p.[T191M]+[I278S] CT Severe Spain 
100 p.[T191M]+[R379Q] CT Mild Spain 
107 c.[1566delG]+[1566delG] CT NA Spain 
108 p.[I278T]+[C275Y] TT Mild Spain 
81 c.[1566delG]+[1566delG] TT Severe Portugal 
87 c.[1566delG]+[532-37_736+438del794] CC neonatal screening 
(asymptomatic) 
Portugal 
109 p.[E289GfsX39]+[E289GfsX39] CT Severe Portugal 
68a p.[G85R]+c.[667-14_667-7del8] CT Severe Argentina 
68b p.[G85R]+c.[667-14_667-7del8] CT Severe  
89 c.[689delT]+[689delT] CT Severe Argentina 
90 p.[D321V]+[A446S] CT Mild Argentina 
91 p.[A226T]+[A226T] CT Severe Argentina 
105 p.[I278T]+[I278T] ND NA Norway 
55 p.[M173del]+[M173del] ND Mild Indian 
ND: Not Determined. 
NA: Not Available. 
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